混合性脂质失调(Mixed Dyslipidemia):这是一种胆固醇和甘油三酯同时异常增高的状况。 2. 使用剂量(Dosage) 瑞舒伐他汀(Rosuvastatin)可定的剂量应根据患者的具体情况和临床需要而定。一般建议的起始剂量是每天5毫克,可以在需要的情况下逐渐调整剂量。最大剂量为每天40毫克。 3. 使用方法(Administration) 瑞舒伐他汀(Ros...
混合性脂质失调则是指血中同时存在高密度脂蛋白胆固醇(HDL-C)降低和LDL-C升高。 2. 用法和剂量(Dosage and Administration) 瑞舒伐他汀(Rosuvastatin)可定的用法和剂量应根据患者的具体情况由医生指导。一般建议开始时使用较低的剂量,并根据患者的反应和需要逐渐调整。瑞舒伐他汀(Rosuvastatin)可定通常口服,可随餐或...
Uses Before taking Overdose Dosage Side effects Interactions What is rosuvastatin?Rosuvastatin (Crestor, Ezallor Sprinkle) is a prescription medication used to treat high cholesterol and prevent heart attacks and strokes.Rosuvastatin belongs to a class of drugs called statins. It works in two ways. ...
通用名称:Crestor 药品规格:20mg 生产企业:英国阿斯利康 功能主治: 用于原发性高胆固醇血症、混合性脂质失调的治疗。 用法用量 1、高胆固醇血症及混合型血脂障碍(高脂蛋白血症Ⅱa和Ⅱb型):口服,推荐起始剂量10mg,常用剂量5～40mg,每日1次,饭前或饭后服用。
Rosuvastatin DosageMedically reviewed by Drugs.com. Last updated on Sep 26, 2024.Applies to the following strengths: 5 mg; 10 mg; 20 mg; 40 mgUsual Adult Dose for: Hyperlipidemia Hyperlipoproteinemia Type III (Elevated beta-VLDL + IDL) Hypertriglyceridemia Atherosclerosis Homozygous Familial ...
An event is serious (FDA MedWatch definition) when the patient outcome is: death life-threatening hospitalisation disability congenital anomaly requires intervention to prevent permanent impairment or damage After 1 year of treatment with rosuvastatin [ dosage and route of administration not stated ] ...
dosage, form, labeller, route of administration, and marketing period. Access now Access drug product information from over 10 global regions. Access now Product Ingredients IngredientUNIICASInChI Key Rosuvastatin calcium 83MVU38M7Q 147098-20-2 LALFOYNTGMUKGG-JGMJEEPBSA-L Rosuvastatin zinc 70VE...
2 DOSAGE AND ADMINISTRATION 2.1 General Dosage and Administration Information Administer rosuvastatin tablets orally as a single dose at any time of day, with or without food. Swallow the tablets whole. Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin tablet...
At this dosage, there is an expected 52% reduction in LDL-C in patients with primary hypercholesterolemia. In these same patients, rosuvastatin produces approximately a 10% increase in HDL-C and a 24% decrease in triglycerides. For patients of advanced age or with renal insufficiency, the ...
Dosage-related elevation of creatine kinase (CK) was observed in patients taking Rosuvastatin; most cases were mild, asymptomatic, and transient. If CK levels increase (>5×ULN), treatment should be discontinued. Effects on the liver: a dose-dependent increase of transaminase was observed in a ...